Research progress of microglia causing and promoting Alzheimer's disease

Abstract

Abstract: Microglia is a kind of immune cell in nervous system and has dual regulatory function. It not only streng then phagocytosis, release anti-inflammatory factors to maintain the homeostasis of brain tissues and protect neurons, but also increase the inflammatory response and reduce the scavenging ability of harmful proteins to damage neurons. Under the influence of aging, the expression of CD33 in microglia increased while the expression of TREM2 decreased. In terms of activated phenotype, microglia in the aged population are more inclined to be activated into a pro-inflammatory phenotype, thus promoting the occurrence and progression of AD. In this paper, the mechanisms of microglia inducing and promoting AD were reviewed from the aspects of microglia gene expression, proinflammatory phenotype and immune regulation, in order to provide new strategy for the treatment of AD through microglia.

Key words: Alzheimer’s disease, microglia, neuroinflammation, immunoregulation

CLC Number:

WANG Zi-han, LUO Jin-ding, TIAN Ying-ru, FENG Shui-dong, LING Hong-yan. Research progress of microglia causing and promoting Alzheimer's disease[J]. Basic & Clinical Medicine, 2021, 41(2): 277-281.

References

[1] Baik SH, Kang S, Lee W, et al. A breakdown in metabolic reprogramming causes microglia dysfunction in Alzheimer's disease[J]. Cell Metab, 2019, 30:493-507.
[2] Chakravorty A, Jetto CT, Manjithaya R. Dysfunctional mitochondria and mitophagy as drivers of Alzheimer's disease pathogenesis[J]. Front Aging Neurosci, 2019, 11:311.
[3] Villegas-Llerena C, Phillips A, Garcia-Reitboeck P, et al. Microglial genes regulating neuroinflammation in the progression of Alzheimer's disease[J]. Curr Opin Neurobiol, 2016, 36:74-81.
[4] Mhatre SD, Tsai CA, Rubin AJ, et al. Microglial malfunction: the third rail in the development of Alzheimer's disease[J]. Trends Neurosci, 2015, 38:621-636.
[5] Heneka MT, Carson MJ, El Khoury J, et al. Neuroinflammation in Alzheimer's disease[J]. Lancet Neurol, 2015, 14:388-405.
[6] Graham WV, Bonito-Oliva A, Sakmar TP. Update on Alzheimer's disease therapy and prevention strategies[J]. Annu Rev Med, 2017, 68:413-430.
[7] Kunkle BW, Grenier-Boley B, Sims R, et al. Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Abeta, tau, immunity and lipid processing[J]. Nat Genet, 2019, 51:414-430.
[8] Griciuc A, Patel S, Federico AN, et al. TREM2 acts downstream of CD33 in modulating microglial pathology in Alzheimer's disease[J]. Neuron, 2019, 103:820-835.
[9] Estus S, Shaw BC, Devanney N, et al. Evaluation of CD33 as a genetic risk factor for Alzheimer's disease[J]. Acta Neuropathol, 2019, 138:187-199.
[10] Ulrich JD, Ulland TK, Colonna M, et al. Elucidating the role of TREM2 in Alzheimer's disease[J]. Neuron, 2017, 94:237-248.
[11] Sims R, van der Lee SJ, Naj AC, et al. Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease[J]. Nat Genet, 2017, 49:1373-1384.
[12] Chen YJ, Nguyen HM, Maezawa I, et al. Inhibition of the potassium channel Kv1.3 reduces infarction and inflammation in ischemic stroke[J]. Ann Clin Transl Neurol, 2018, 5:147-161.
[13] Che RX, Xing XX, Liu X, et al. Analysis of multidrug resistance in streptococcus suis ATCC 700794 under tylosin stress[J]. Virulence, 2019, 10:58-67.
[14] Zhong L, Chen XF, Wang T, et al. Soluble TREM2 induces inflammatory responses and enhances microglial survival[J]. J Exp Med, 2017, 214:597-607.
[15] Ulland TK, Song WM, Huang SC, et al. TREM2 maintains microglial metabolic fitness in Alzheimer's disease[J]. Cell, 2017, 170:649-663.
[16] Maezawa I, Nguyen HM, Di Lucente J, et al. Kv1.3 inhibition as a potential microglia-targeted therapy for Alzheimer's disease: preclinical proof of concept[J]. Brain, 2018, 141:596-612.
[17] Mullard A. Microglia-targeted candidates push the Alzheimer drug envelope[J]. Nat Rev Drug Discov, 2018, 17:303-305.
[18] Almolda B, de Labra C, Barrera I, et al. Alterations in microglial phenotype and hippocampal neuronal function in transgenic mice with astrocyte-targeted production of interleukin-10[J]. Brain Behav Immun, 2015, 45:80-97.
[19] Ransohoff RM. How neuroinflammation contributes to neurodegeneration[J]. Science, 2016, 353:777-783.
[20] Heckmann BL, Teubner BJW, Tummers B, et al. LC3-associated endocytosis facilitates beta-amyloid clearance and mitigates neurodegeneration in murine Alzheimer's disease[J]. Cell, 2019, 178:536-551.
[21] 李杰, 周军媚, 田绍文. 小胶质细胞生物学特性及对神经元调控作用[J]. 基础医学与临床, 2018, 38:563-567.
[22] Voet S, Srinivasan S, Lamkanfi M, et al. Inflammasomes in neuroinflammatory and neurodegenerative diseases[J]. EMBO Mol Med, 2019, 11:e10248. doi:10.15252/emmm.201810248.
[23] Freeman L, Guo H, David CN, et al. NLR members NLRC4 and NLRP3 mediate sterile inflammasome activation in microglia and astrocytes[J]. J Exp Med, 2017, 214:1351-1370.
[24] Hong S, Beja-Glasser VF, Nfonoyim BM, et al. Complement and microglia mediate early synapse loss in Alzheimer mouse models[J]. Science, 2016, 352:712-716.